WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 317201
CAS#: 129722-12-9 (free base)
Description: Aripiprazole, sold under the brand name Abilify among others, is an atypical antipsychotic. It is recommended and primarily used in the treatment of schizophrenia and bipolar disorder. Other uses include as an add-on treatment in major depressive disorder, tic disorders, and irritability associated with autism. Aripiprazole is a quinoline derivate and atypical anti-psychotic agent. Aripiprazole has partial agonistic activity at dopamine D2 receptors and serotonin 5-HT1A receptors, as well as potent antagonistic activity on serotonin 5-HT2A receptors.
MedKoo Cat#: 317201
Name: Aripiprazole
CAS#: 129722-12-9 (free base)
Chemical Formula: C23H27Cl2N3O2
Exact Mass: 447.14803
Molecular Weight: 448.39
Elemental Analysis: C, 61.61; H, 6.07; Cl, 15.81; N, 9.37; O, 7.14
Aripiprazole, purity > 98%, is in stock. The same day shipping after order is received.
Related CAS #: 129722-12-9 (free base) 851220-85-4 (hydrate) 1259305-26-4 (cavoxil) 1259305-29-7 (lauroxil)
Synonym: OPC-14597; OPC 14597; OPC14597; Abilify; Abilitat; Abilify Discmelt.
IUPAC/Chemical Name: 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
InChi Key: CEUORZQYGODEFX-UHFFFAOYSA-N
InChi Code: InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)
SMILES Code: C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl
The following data is based on the product molecular weight 448.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Grall-Bronnec M, Sauvaget A, Perrouin F, Leboucher J, Etcheverrigaray F, Challet-Bouju G, Gaboriau L, Derkinderen P, Jolliet P, Victorri-Vigneau C. Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review. J Clin Psychopharmacol. 2015 Dec 12. [Epub ahead of print] PubMed PMID: 26658263.
2: Diomšina B, Rasmussen PD, Danilevičiütė V. CLINICAL EXPERIENCE OF LONG-TERM TREATMENT WITH ARIPIPRAZOLE (ABILIFY) IN CHILDREN AND ADOLESCENTS AT THE CHILD AND ADOLESCENT PSYCHIATRIC CLINIC 1 IN ROSKILDE, DENMARK. Acta Pol Pharm. 2015 May-Jun;72(3):597-606. PubMed PMID: 26642668.
3: Monga V, Padala PR. Aripiprazole for Treatment of Apathy. Innov Clin Neurosci. 2015 Sep-Oct;12(9-10):33-6. PubMed PMID: 26634180; PubMed Central PMCID: PMC4655898.
4: Tokisato K, Fukunaga K, Tokunaga M, Watanabe S, Nakanishi R, Yamanaga H. Aripiprazole Can Improve Apraxia of Eyelid Opening in Parkinson's Disease. Intern Med. 2015;54(23):3061-4. doi: 10.2169/internalmedicine.54.4279. Epub 2015 Dec 1. PubMed PMID: 26631893.
5: Palaniappan P. Aripiprazole as a treatment option for clozapine-induced enuresis. Indian J Pharmacol. 2015 Sep-Oct;47(5):574-5. doi: 10.4103/0253-7613.165176. PubMed PMID: 26600658; PubMed Central PMCID: PMC4621690.
6: Frank GK. Aripiprazole, a partial dopamine agonist to improve adolescent anorexia nervosa-A case series. Int J Eat Disord. 2015 Nov 23. doi: 10.1002/eat.22485. [Epub ahead of print] PubMed PMID: 26593328.
7: Prommer E. Aripiprazole: A New Option in Delirium. Am J Hosp Palliat Care. 2015 Nov 20. pii: 1049909115612800. [Epub ahead of print] PubMed PMID: 26589880.
8: Burback L. Management of a microprolactinoma with aripiprazole in a woman with cabergoline-induced mania. Endocrinol Diabetes Metab Case Rep. 2015;2015:150100. doi: 10.1530/EDM-15-0100. Epub 2015 Oct 6. PubMed PMID: 26587235; PubMed Central PMCID: PMC4650831.
9: Citrome L. Aripiprazole Long-Acting Injectable Formulations for Schizophrenia: Aripiprazole Monohydrate and Aripiprazole Lauroxil. Expert Rev Clin Pharmacol. 2015 Nov 17. [Epub ahead of print] PubMed PMID: 26573020.
10: Suzuki H, Sekiguchi G. The influence of aripiprazole once-monthly on the clinical symptoms and cognitive function in two schizophrenia patients: preliminary results. Psychiatry Clin Neurosci. 2015 Nov 10. doi: 10.1111/pcn.12374. [Epub ahead of print] PubMed PMID: 26556467.
